The present invention relates to transcatheter valve prostheses that are radially expandable by a balloon.
A human heart includes four heart valves that determine the pathway of blood flow through the heart: the mitral valve, the tricuspid valve, the aortic valve, and the pulmonary valve. The mitral and tricuspid valves are atrioventricular valves, which are between the atria and the ventricles, while the aortic and pulmonary valves are semilunar valves, which are in the arteries leaving the heart. Ideally, native leaflets of a heart valve move apart from each other when the valve is in an open position, and meet or “coapt” when the valve is in a closed position. Problems that may develop with valves include stenosis in which a valve does not open properly, and/or insufficiency or regurgitation in which a valve does not close properly. Stenosis and insufficiency may occur concomitantly in the same valve. The effects of valvular dysfunction vary, with regurgitation or backflow typically having relatively severe physiological consequences to the patient.
Recently, flexible prosthetic valves supported by stent structures that can be delivered percutaneously using a catheter-based delivery system have been developed for heart and venous valve replacement. These prosthetic valves may include either self-expanding or balloon-expandable stent structures with valve leaflets attached to the interior of the stent structure. The prosthetic valve can be reduced in diameter, by crimping onto a balloon catheter or by being contained within a sheath component of a delivery catheter, and advanced through the venous or arterial vasculature. Once the prosthetic valve is positioned at the treatment site, for instance within an incompetent native valve, the stent structure may be expanded to hold the prosthetic valve firmly in place.
When designing a prosthetic valve, valve-stent integration and stent mechanical performance often have competing needs or requirements. For example, when attaching the valve to the stent during valve-stent integration, the valve itself needs to be reinforced to the stent at certain locations without hindering mechanical performance of the stent. Embodiments hereof relate to an improved balloon-expandable transcatheter valve prosthesis configured to minimize tradeoffs between the above-described competing needs.
Embodiments hereof relate to a transcatheter valve prosthesis including a stent and a prosthetic valve. The stent has a crimped configuration for delivery within a vasculature and an expanded configuration for deployment within a native heart valve. The stent is balloon expandable. The stent includes an inflow portion formed proximate to an inflow end of the transcatheter valve prosthesis, an outflow portion formed proximate to an outflow end of the transcatheter valve prosthesis, and a transition portion extending between the inflow portion and the outflow portion. The prosthetic valve is disposed within and secured to the stent. The prosthetic valve is configured to block blood flow in one direction to regulate blood flow through a central lumen of the stent. A diameter of the inflow end of the transcatheter valve prosthesis is greater than a diameter of the outflow end of the transcatheter valve prosthesis. The stent has a tapered profile along a portion of the height thereof when in the stent is in the expanded configuration. The inflow end of the transcatheter valve prosthesis is configured to sit within and contact an aortic annulus of the native aortic valve and the outflow end of the transcatheter valve prosthesis being configured to float within an ascending aorta without substantially contacting the ascending aorta due to the tapered profile of the transcatheter valve prosthesis.
The foregoing and other features and advantages of the invention will be apparent from the following description of embodiments hereof as illustrated in the accompanying drawings. The accompanying drawings, which are incorporated herein and form a part of the specification, further serve to explain the principles of the invention and to enable a person skilled in the pertinent art to make and use the invention. The drawings are not to scale.
Specific embodiments of the present invention are now described with reference to the figures, wherein like reference numbers indicate identical or functionally similar elements. The terms “distal” and “proximal”, when used in the following description to refer to a native vessel, native valve, or a device to be implanted into a native vessel or native valve, such as a heart valve prosthesis, are with reference to the direction of blood flow. Thus, “distal” and “distally” refer to positions in a downstream direction with respect to the direction of blood flow and the terms “proximal” and “proximally” refer to positions in an upstream direction with respect to the direction of blood flow.
The following detailed description is merely exemplary in nature and is not intended to limit the invention or the application and uses of the invention. Although the description of the invention is in the context of treatment of an aortic heart valve, the invention may also be used where it is deemed useful in other valved intraluminal sites that are not in the heart. For example, the present invention may be applied to other heart valves or venous valves as well. Furthermore, there is no intention to be bound by any expressed or implied theory presented in the preceding technical field, background, brief summary or the following detailed description.
Referring to
The stent 102 of the transcatheter valve prosthesis 100 is a frame or scaffold that supports the prosthetic valve 132 including one or more valve leaflets 134 within the interior of the stent 102. The prosthetic valve 132 is capable of blocking flow in one direction to regulate flow there-through via the valve leaflets 134 that may form a bicuspid or tricuspid replacement valve.
The valve leaflets 134 may be made of pericardial material; however, the valve leaflets 134 may instead be made of another material. Natural tissue for the valve leaflets 134 may be obtained from, for example, heart valves, aortic roots, aortic walls, aortic leaflets, pericardial tissue, such as pericardial patches, bypass grafts, blood vessels, intestinal submucosal tissue, umbilical tissue and the like from humans or animals. Synthetic materials suitable for use as the valve leaflets 134 include DACRON® polyester commercially available from Invista North America S.A.R.L. of Wilmington, Del., other cloth materials, nylon blends, polymeric materials, and vacuum deposition nitinol fabricated materials. One polymeric material from which the leaflets can be made is an ultra-high molecular weight polyethylene material commercially available under the trade designation DYNEEMA from Royal DSM of the Netherlands. With certain leaflet materials, it may be desirable to coat one or both sides of the leaflet with a material that will prevent or minimize overgrowth. It is further desirable that the leaflet material is durable and not subject to stretching, deforming, or fatigue.
Graft material 144 may enclose or line the stent 102 as would be known to one of ordinary skill in the art of prosthetic tissue valve construction. Graft material 144 may be a natural or biological material such as pericardium or another membranous tissue such as intestinal submucosa. Alternatively, graft material 144 may be a low-porosity woven fabric, such as polyester, Dacron fabric, or PTFE, which creates a one-way fluid passage when attached to the stent. In one embodiment, graft material 144 may be a knit or woven polyester, such as a polyester or PTFE knit, which can be utilized when it is desired to provide a medium for tissue ingrowth and the ability for the fabric to stretch to conform to a curved surface. Polyester velour fabrics may alternatively be used, such as when it is desired to provide a medium for tissue ingrowth on one side and a smooth surface on the other side. These and other appropriate cardiovascular fabrics are commercially available from Bard Peripheral Vascular, Inc. of Tempe, Ariz., for example.
As previously stated, the stent 102 is balloon-expandable as would be understood by one of ordinary skill in the art. As such, the stent 102 is made from a plastically deformable material such that when expanded by a dilatation balloon, the stent 102 maintains its radially expanded configuration. The stent 102 may be formed from stainless steel or other suitable metal, such as platinum iridium, cobalt chromium alloys such as MP35N, or various types of polymers or other materials known to those skilled in the art, including said materials coated with various surface deposits to improve clinical functionality. The stent 102 is configured to be rigid such that it does not deflect or move when subjected to in-vivo forces, or such that deflection or movement is minimized when subjected to in-vivo forces. In an embodiment, the radial stiffness (i.e., a measurement of how much the stent 102 deflects when subjected to in-vivo forces) of the stent 102 is between 80 N/m and 120 N/m, and the radial stiffness of the stent 102 scaled across the deployed height thereof is approximately 5 N/mm2. In an embodiment, the radial stiffness of the stent 102 is greater than 100 N/m. Further, in an embodiment, the device recoil (i.e., a measurement of how much the stent 102 relaxes after balloon deployment) is below 15% and the approximately recoil after deployment is between 1 mm and 2 mm. Further, in an embodiment, the device crush or yield (i.e., the radial force at which the stent 102 yields) is approximately 200 N.
As previously stated, the transcatheter valve prosthesis 100 is configured for replacement for an aortic valve such that the inflow end 106 of the transcatheter valve prosthesis 100 is configured to sit within and contact an aortic annulus of the native aortic valve and the outflow end 116 of the transcatheter valve prosthesis 100 is configured to float freely within the outflow track without contacting or without substantially contacting the walls of the ascending aorta due to the tapered profile of the transcatheter valve prosthesis 100. More particularly, due to the tapered profile, the outflow end 116 of the transcatheter valve prosthesis 100 does not interact with or touch the surrounding anatomy, i.e., the walls of the ascending aorta. Further, the tapered profile of the transcatheter valve prosthesis 100 prevents valve interaction with the anatomy of the aortic valve, particularly the sino tubular junction anatomy. As will be described in more detail herein with respect to
The transcatheter valve prosthesis 100 is configured for supra annular placement within a native aortic valve such that the prosthetic valve 132 sits superior to or downstream of the native leaflets of the native aortic valve when implanted in situ. A height or length of the stent 102 in the expanded configuration is between 22 and 33 mm, the height being measured from the most proximal part thereof (endmost inflow crowns 110A, which will be described in more detail herein) to the most distal part thereof (endmost outflow crowns 120A, which will be described in more detail herein). Stated another way, the height of the stent 102 in the expanded configuration is measured from a proximal end of the stent to a distal end of the stent. In an embodiment hereof, a height or length of the stent 102 in the expanded configuration is approximately 30 mm. The height or length of the stent 102 may vary from that depicted herein in order to accommodate dimensions of the native valve anatomy. In another embodiment hereof, the transcatheter valve prosthesis 100 is configured for intra annular placement within a native aortic valve such that the prosthetic valve 132 sits within the native leaflets of the native aortic valve when implanted in situ.
The stent 102 will now be described in more detail. The stent 102 includes an inflow portion 108, an outflow portion 118, and a transition portion 124 bridging, connecting, or otherwise extending between the inflow portion 108 and the outflow portion 118. The stent 102 is a generally tubular component defining a central lumen or passageway 142, and includes an inflow or proximal end 107 that defines the inflow or proximal end 106 of the transcatheter valve prosthesis and an outflow or distal end 117 that defines the outflow or distal end 116 of the transcatheter valve prosthesis 100. The stent 102 may be formed by a laser-cut manufacturing method and/or another conventional stent forming method as would be understood by one of ordinary skill in the art. The cross-section of the stent 102 may be circular, ellipsoidal, rectangular, hexagonal, square, or other polygonal shape, although at present it is believed that circular or ellipsoidal may be preferable with the transcatheter valve prosthesis 100 being provided for replacement of an aortic valve. The stent 102 has an expanded configuration, which is shown in the perspective and side views of
The inflow portion 108 of the stent 102 is formed proximate to the inflow end 107 of the stent 102. The inflow portion 108 includes a plurality of crowns 110 and a plurality of struts 112 with each crown 110 being formed between a pair of opposing struts 112. Each crown 110 is a curved segment or bend extending between opposing struts 112. The inflow portion 108 is generally tubular, with a plurality of cells or side openings 114 being defined by the plurality of crowns 110 and the plurality of struts 112. In an embodiment, the plurality of side openings 114 may be diamond-shaped. More particularly, as best shown in
The outflow portion 118 of the stent 102 is formed proximate to the outflow end 117 of the stent 102. The outflow portion 118 includes a plurality of crowns 120 and a plurality of struts 122 with each crown 120 being formed between a pair of opposing struts 122. Each crown 120 is a curved segment or bend extending between opposing struts 122. The outflow portion 118 is a ring. A series of endmost outflow crowns 120A are formed at the outflow end 117 of the stent 102. The outflow end 117 has a total of six endmost outflow crowns 120A, as best shown in
The transition portion 124 bridges, connects, or otherwise extends between the inflow portion 108 and the outflow portion 118. The transition portion 124 includes a total of six axial frame members 126, each axial frame member 126 extending between a crown 120 of the outflow portion 118 and a crown 110 of the inflow portion 108. More particularly, each axial frame member 126 is an axial segment having a first end 128 connected to a crown 120 of the outflow portion 118 and a second end 130 connected to a crown 110 of the inflow portion 108. The axial frame members 126 are substantially parallel to the central longitudinal axis of the stent 102 taking into account the angle of the taper, described below. Each axial frame member 126 is disposed approximately halfway between a pair of adjacent endmost outflow crowns 120A. Three of the six axial frame members 126 are commissure posts 126A and aligned with and attached to a respective commissure of the three leaflets 134 of the prosthetic valve 132. Three of the axial frame members 126 are axial struts 126B and each is disposed between adjacent commissure posts 126A. In this embodiment, the endmost outflow crowns 120A of are not connected to axial frame members 126 of the transition portion 124 but rather may be considered to be free or unattached while the remaining outflow crowns 120 of the outflow portion 118 are connected to the axial frame members 126 and disposed closer to the inflow end 106 than the endmost outflow crowns 120A. The axial frame members 126 aid in valve alignment and coaptation. More particularly, since commissure posts 126A are used as connection locations for the commissures of the three leaflets 134 of the prosthetic valve 132, the commissure posts 126A shape the leaflets 134 and reinforce, strength, or otherwise support the leaflets 134 during opening and closing thereof, thereby providing more reliable leaflet alignment and coaptation. In addition, the axial frame members 126 minimize the crossing profile of the transcatheter valve prosthesis 100 since the axial frame members 126 are circumferentially spaced apart from each other while maximizing symmetrical cell expansion of the stent 102 since the axial frame members 126 are spaced at generally the same distance from each other around the periphery of the stent 102. Symmetrical cell expansion ensures that the stent 102 crimps well onto a balloon of a balloon catheter for delivery. Poor crimp quality may lead to portions of the stent overlapping when crimped, which in turn may cause tissue damage to the valve leaflets of the prosthetic valve during the crimping process.
The prosthetic valve 132 is disposed within and secured to at least the transition portion 124 of the stent 102 at the commissure posts 126A. In addition, the prosthetic valve 132 may also be disposed within and secured to the inflow portion 108 of the stent 102 and/or the outflow portion 116 of the stent 102.
In the embodiment shown, there is a single row of struts 122 and crowns 120 between the first ends 128 of the axial frame members 126 and the outflow end 117 of the stent 102. Further, in the embodiment shown, exactly two struts 122 and a single crown 120 of the outflow portion 118 are disposed between circumferentially adjacent axial frame members 126. Such an arrangement provides a series of six endmost outflow cells or side openings 125 formed at the outflow portion 118 of the stent 102. Each endmost outflow side opening 125 is generally heart-shaped. More particularly, as best shown in
Also in the embodiment shown, the inflow portion 108 includes exactly four rows of struts 112 and crowns 110 between the second ends 130 of the axial frame members 126 and the inflow end 107 of the stent 102. Further, four struts 112 and three crowns 110 of the inflow portion are disposed between the second ends 130 of circumferentially adjacent axial frame members 126.
Following implantation of the transcatheter valve prosthesis 100, it may be desirable to access a coronary artery CA. As shown in
More particularly,
While various embodiments according to the present invention have been described above, it should be understood that they have been presented by way of illustration and example only, and not limitation. It will be apparent to persons skilled in the relevant art that various changes in form and detail can be made therein without departing from the spirit and scope of the invention. Thus, the breadth and scope of the present invention should not be limited by any of the above-described exemplary embodiments, but should be defined only in accordance with the appended claims and their equivalents. It will also be understood that each feature of each embodiment discussed herein, and of each reference cited herein, can be used in combination with the features of any other embodiment. All patents and publications discussed herein are incorporated by reference herein in their entirety.
This application claims the benefit of U.S. Provisional Patent Application Ser. No. 62/849,208, filed May 17, 2019, which is hereby incorporated by reference in its entirety for all purposes.
Number | Name | Date | Kind |
---|---|---|---|
5330500 | Song | Jul 1994 | A |
5411552 | Andersen et al. | May 1995 | A |
5840081 | Andersen et al. | Nov 1998 | A |
5931969 | Carpentier et al. | Aug 1999 | A |
6168614 | Andersen et al. | Jan 2001 | B1 |
6210957 | Carpentier et al. | Apr 2001 | B1 |
6214054 | Cunanan et al. | Apr 2001 | B1 |
6458153 | Bailey et al. | Oct 2002 | B1 |
6547827 | Carpentier et al. | Apr 2003 | B2 |
6561970 | Carpentier et al. | May 2003 | B1 |
6582462 | Andersen et al. | Jun 2003 | B1 |
6730118 | Spenser et al. | May 2004 | B2 |
6830584 | Sequin | Dec 2004 | B1 |
6893460 | Spenser et al. | May 2005 | B2 |
6908481 | Cribier | Jun 2005 | B2 |
7018406 | Seguin et al. | Mar 2006 | B2 |
7198646 | Figulia et al. | Apr 2007 | B2 |
7201772 | Schwammenthal et al. | Apr 2007 | B2 |
7214344 | Carpentier et al. | May 2007 | B2 |
7252682 | Seguin | Aug 2007 | B2 |
7329278 | Seguin et al. | Feb 2008 | B2 |
7393360 | Spenser et al. | Jul 2008 | B2 |
7429269 | Schwammenthal et al. | Sep 2008 | B2 |
7442204 | Schwammenthal et al. | Oct 2008 | B2 |
RE40570 | Carpentier et al. | Nov 2008 | E |
7470285 | Nugent et al. | Dec 2008 | B2 |
7510575 | Spenser et al. | Mar 2009 | B2 |
7530253 | Spenser et al. | May 2009 | B2 |
7585321 | Cribier | Sep 2009 | B2 |
7618446 | Andersen et al. | Nov 2009 | B2 |
7682390 | Seguin | Mar 2010 | B2 |
7780723 | Taylor | Aug 2010 | B2 |
7780726 | Seguin | Aug 2010 | B2 |
7789909 | Andersen et al. | Sep 2010 | B2 |
7846203 | Cribier | Dec 2010 | B2 |
7993394 | Hariton et al. | Aug 2011 | B2 |
8163011 | Rankin | Apr 2012 | B2 |
8236045 | Benichou et al. | Aug 2012 | B2 |
8579966 | Seguin | Nov 2013 | B2 |
8926694 | Costello | Jan 2015 | B2 |
9089422 | Ryan et al. | Jul 2015 | B2 |
9901447 | Braido et al. | Feb 2018 | B2 |
9943407 | Tuval et al. | Apr 2018 | B2 |
10058420 | Levi | Aug 2018 | B2 |
20060178740 | Stacchino et al. | Aug 2006 | A1 |
20060259137 | Artof et al. | Nov 2006 | A1 |
20070078510 | Ryan | Apr 2007 | A1 |
20070270944 | Bergheim et al. | Nov 2007 | A1 |
20080154355 | Benichou et al. | Jun 2008 | A1 |
20090192591 | Ryan et al. | Jul 2009 | A1 |
20100268332 | Tuval et al. | Oct 2010 | A1 |
20110015729 | Jimenez et al. | Jan 2011 | A1 |
20110166636 | Rowe | Jul 2011 | A1 |
20110264196 | Savage | Oct 2011 | A1 |
20110301700 | Fish et al. | Dec 2011 | A1 |
20110313515 | Quadri et al. | Dec 2011 | A1 |
20120053681 | Alkhatib et al. | Mar 2012 | A1 |
20120071969 | Li et al. | Mar 2012 | A1 |
20120078356 | Fish et al. | Mar 2012 | A1 |
20130023984 | Conklin | Jan 2013 | A1 |
20130150956 | Yohanan | Jun 2013 | A1 |
20130184811 | Rowe et al. | Jul 2013 | A1 |
20140277389 | Braido et al. | Sep 2014 | A1 |
20140330371 | Gloss | Nov 2014 | A1 |
20150018944 | O'Connell et al. | Jan 2015 | A1 |
20190091014 | Arcaro | Mar 2019 | A1 |
20200078167 | Quijano | Mar 2020 | A1 |
20220160502 | Jin | May 2022 | A1 |
Number | Date | Country |
---|---|---|
2003011195 | Feb 2003 | WO |
20060127765 | Nov 2006 | WO |
2008150529 | Dec 2008 | WO |
2012032187 | Mar 2012 | WO |
Number | Date | Country | |
---|---|---|---|
20200360134 A1 | Nov 2020 | US |
Number | Date | Country | |
---|---|---|---|
62849208 | May 2019 | US |